US20110287081A1 - Bolus - Google Patents

Bolus Download PDF

Info

Publication number
US20110287081A1
US20110287081A1 US13/131,260 US200913131260A US2011287081A1 US 20110287081 A1 US20110287081 A1 US 20110287081A1 US 200913131260 A US200913131260 A US 200913131260A US 2011287081 A1 US2011287081 A1 US 2011287081A1
Authority
US
United States
Prior art keywords
bolus
casing
tablets
core
tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/131,260
Inventor
Wayne Frederick Leech
William Ernest Pomroy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer New Zealand Ltd
Original Assignee
Bomac Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bomac Research Ltd filed Critical Bomac Research Ltd
Assigned to BOMAC RESEARCH LIMITED reassignment BOMAC RESEARCH LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LEECH, WAYNE FREDERICK, POMROY, WILLIAM ERNEST
Publication of US20110287081A1 publication Critical patent/US20110287081A1/en
Assigned to BAYER NEW ZEALAND LIMITED reassignment BAYER NEW ZEALAND LIMITED MERGER (SEE DOCUMENT FOR DETAILS). Assignors: BOMAC RESEARCH LIMITED
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0068Rumen, e.g. rumen bolus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics

Definitions

  • the present invention relates to an improved bolus.
  • the invention relates to an improved bolus and method of manufacture using coatings to prevent variation in bolus erosion rates.
  • a wide variety of boli have been used for treatment of livestock such as cows and sheep over many years.
  • the basic premise of the bolus is that an active agent is delivered to the animal over an extended period of time.
  • An advantage of this method of delivery is that the farmer or livestock manager need only administer the bolus once for delivery over an extended period of time rather than having to administer a medication on a more frequent e.g. daily basis.
  • Existing boli may have a useful time period of over one month and therefore this may reduce labour and material costs.
  • the bolus described in U.S. Pat. No. 4,649,042 (equivalent to NZ212181) comprises a biodegradable polymeric core impregnated with medicament that is encased in a stainless steel tube with end caps and an arrangement of holes to allow the passage of rumen fluid to the biodegradable core.
  • a layer of settable and/or elastic sealant holds the core in place and prevents seepage of rumen fluid between the walls of the bolus (the tube) and the core which would result in unpredictable delivery of medicament.
  • the required physical properties of the sealant are described as ‘the ability to form a moisture-tight adhesive bond to the polymeric core and to the tube, and a high degree of water impermeability to prevent permeation of water through the layer of sealant to the sides of the core.
  • sealant be sufficiently cohesive and elastic to absorb relative movement of the core and tube during thermal expansion and contraction over the temperature range encountered in storage and use, from about ⁇ 20° C. to about 50° C.
  • settable sealants do not necessarily break down at the same rate as the tablet core. It can be that the settable coatings protects portions of the tablet core better than other portions, leading to inconsistent rates of erosion of the tablet, depending on how the tablet core is physically eroded.
  • settable sealant can break away in large sections from the bolus, thus becoming a non-contiguous coating along portions of the tablet core. This exposes a much greater portion of the tablet core to the rumen fluid than is ideal, and again, can lead to inconsistent rates of erosion of the tablet.
  • the spent metal shell of the bolus remains in the rumen after all the biologically active material has been released or paid out. This can cause a problem during slaughter of the animal particularly since the bolus is made of metal which can be hazardous or damage cutting equipment used in slaughter and processing.
  • NZ220024 Another type of bolus described in NZ220024 (equivalent to U.S. Pat. No. 4,863,455) attempts to resolve the problem of residues left in the animal.
  • NZ220024 describes a bolus for administration to a ruminant. It comprises a magnesium-alloy tube filed with a core of a mixture of biologically active material and electronically conductive material lower in the electrochemical series than magnesium. The corrosion is galvanic in nature with a potential difference existing between the tube and core.
  • the tube may be provided with a resin or plastic sheath on its exterior surface to protect the walls of the tube from corrosion by rumen juices.
  • a tube ending is left unprotected to allow gradual corrosion down the length of the tube ideally at the unprotected face.
  • the core may be a single tablet or a series of tablets which are formed in a pelleting die and introduced into the tube or alternatively the ingredients can be forced into the tube using a hydraulic or mechanical press to form a single tablet.
  • the tablet or tablets are said to form a “close fit” with the tube.
  • the use of a series of tablets allows for sequential dosing of different active ingredients or pulse dosing of the same ingredient by having alternate tablets with and without an active ingredient.
  • the above type of bolus has the advantage that all or a substantial amount of the bolus dissolves in the rumen with any remaining parts being excreted.
  • the rate of erosion from a bolus may be maintained at an approximately constant rate. If the animal receives a dose greater than that desired, for example by a fast erosion rate or breakdown, release of the active agent may also be at a faster level and therefore may be harmful to the animals.
  • a fast erosion rate may give a false sense of security to the farmer in that the animal may have a shorter duration of agent delivery than that expected.
  • a fast release rate may also be toxic to the animal.
  • the erosion rate is too slow, the animal may receive insufficient active agent for the application required.
  • low dosage can result in the development of drug resistance.
  • One issue in arriving at smooth erosion rate is that of egress of rumen fluids into the bolus causing erosion at more than just the interface of the bolus with the fluid.
  • one potential mode of egress is by capillary action with rumen fluid travelling down the inside of the alloy casing and thereby eroding the outside surface of a tablet or tablets contained in the core.
  • capillary action may dissolve a tablet that is not at the designed interface causing both the interface tablet and tablet behind the initial interface to dissolve simultaneously and be released into the animal's bloodstream concurrently, thereby increasing the dose momentarily before a potential ‘no dose’ time period after the tablets erode and a new tablet begins delivery.
  • this variation can have significant negative effects. For example, an increased dose could be harmful to the animal. Also the ‘no dose’ time period allows parasites to grow and multiply resulting in loss of livestock condition.
  • the first relates to disposability of the bolus from the animal rumen and the second of controlling erosion rate and avoiding egress of rumen fluids into the bolus too early thereby influencing agent dosing and bolus duration of action.
  • a bolus for administration to a ruminant by deposition into its rumen having a construction including:
  • the term ‘permanently amorphous’ refers to the coating layer being a non-settable substance that slows the rate of erosion of the core by rumen fluids.
  • extrusion refers to the breakdown into particulate form that occurs when the bolus casing and tablet(s) are exposed to rumen fluids or other aqueous solutions.
  • the invention broadly relates to a bolus for use in ruminants which delivers an active agent or agents to the animal.
  • the bolus includes a casing which contains a core of one or more tablets that may include biologically active agents.
  • the casing is made of an alloy of some type, but this should not be seen as limiting.
  • Other casing materials may be used, for example biodegradable plastic or cellulose.
  • the casing defines a tube shape with an approximately circular cross-section. It should be appreciated that other shapes may also be used such as ellipses or cuboid shapes but a tube is preferable for easy tooling and manufacture since most tabulating machines produce tablets in a circular shape.
  • the casing may be coated with a water impermeable material such as plastic or rubber on its outer surface to prevent the casing from being corroded on selected surfaces by rumen fluid.
  • a water impermeable material such as plastic or rubber
  • each distal end of the bolus tube may be left uncovered. Rumen fluids then erode the uncovered ends of the bolus eroding back the facing tablet and casing cross-section.
  • one end of the bolus is also covered in water impermeable plastic so that erosion occurs only at the opposing distal end of the bolus.
  • the water impermeable coating is a series of plastic rings on the outer surface that are intermeshed together to form a liquid impermeable surface.
  • the rings are intermeshed using a tongue and groove joint between rings. As the casing and core tablets erode, the rings become loose and eventually fall away from the bolus and are excreted from the rumen.
  • This bolus has the advantage of the bolus structure either eroding away as particles or as small rings which are excreted by the animal with few if any residues. Any metal used such as an alloy casing are dissolved and therefore remove any slaughter and processing issues. As noted in the background section above, a disadvantage of many existing devices, particularly those including metals, is that they remain present in the rumen and, when the animal is sent to slaughter, can damage freezing works machinery.
  • the core includes one or more tablets which is eroded by rumen fluid to release active agents which may be beneficial to the animal being treated.
  • the active agents may include anthelmintic compounds such as abamectin and ivermectin and the bolus administered to control to parasite infestation.
  • anthelmintic compounds such as abamectin and ivermectin
  • the bolus When introduced to the rumen, the bolus slowly erodes due to mixing with rumen fluids, releasing active agent from the tablet or tablets.
  • the active agents may be nutritional supplements such as vitamins or the like.
  • the core material may contain electronically conductive material lower in the electrochemical series than the alloy used for the bolus casing.
  • the corrosion is galvanic in nature with a potential difference existing between the alloy casing and core.
  • the permanently amorphous coating alters the corrosion pattern.
  • each tablet included in the core contains at least one active agent mixed with electronically conductive material lower in the electrochemical series.
  • the electronically conductive material lower in the electrochemical series is graphite.
  • the alloy is magnesium based with magnesium comprising approximately 70 to 98% of the alloy.
  • Such alloys are known in the art and erode in the presence of rumen fluids, particularly where the core includes electronically conductive material lower in the electrochemical series, yet maintain their structural integrity when stored in the absence of aqueous solutions.
  • the aim is to control or further manipulate the rate of galvanic corrosion using at least one permanently amorphous substance.
  • each active containing tablet may be interspaced with a blank or non-active containing tablet.
  • blank tablets are preferably formed from graphite and active containing tablets in this embodiment may be formed from a starch base.
  • active agent may be carried in the graphite and the remaining tablets may be starch based blanks.
  • the permanently amorphous substance is an oily or oil based substance.
  • the permanently amorphous substance may be a silicone based grease.
  • the permanently amorphous substance has a similar viscosity to VaselineTM or is a petroleum jelly like VaselineTM, although other permanently amorphous substances with lower viscosities may also be used without departing from the scope of the invention.
  • Such substances include oils such as linseed oil and mineral oils such as liquid paraffin.
  • the permanently amorphous substance may be applied in various ways to the core of the bolus.
  • the location of where the tablet(s) have the substance applied will influence the rate and/or smoothness of release. For example, in applications where there is some tolerance for variation in the speed of release, only the tablet face(s) need have the substance coated.
  • each tablet may be coated.
  • the tablet(s) may only be coated on the outer ring area and the face(s) remain uncovered. It should therefore be appreciated that by varying the location of the coating, the erosion rate may be controlled.
  • a permanently amorphous coating such as VaselineTM
  • the settable coating can crack or otherwise fail, permitting undesired ingress of rumen fluid to the core.
  • a further advantage is the amorphous nature of the coating of the present invention allows it to better fill in any gaps, cracks or other flaws that may be present or develop in the bolus casing or tablet core.
  • Settable coatings are relatively inflexible once set, so any flaws in the bolus casing or tablet core which may develop after the coating has set may not be adequately protected.
  • a bolus including a casing and a core containing tablets for delivery of an active agent or agents to the rumen of an animal wherein the method includes the steps of:
  • the tablet or tablets used in the core are formed in a pelleting die sized such that the tablet or tablets form a snug fit within the casing.
  • the casing is packed with both active agent tablets and blank or non-active agent tablets.
  • these are also at least partially coated in a permanently amorphous substance.
  • the casing is coated with a water impermeable material after step (c) with either one or both ends of the bolus not covered in water impermeable material.
  • the casing is coated with a water permeable material before step (c) with either one or both ends of the bolus left open and uncovered.
  • the method utilises permanently amorphous substances such as oils to in effect slow the egress of rumen fluids and therefore smooth out the rate of erosion compared to that which would be observed if no permanently amorphous substances were used.
  • oils as the permanently amorphous substance reduce the capillary action that may take place in the alloy casing, which contributes to a consistent erosion rate.
  • FIG. 1 illustrates a perspective view of a bolus used in trials
  • FIG. 2 shows a graph of Bolus 1—MT30—VaselineTM erosion as measured by the mean length of alloy (mm) measured by week;
  • FIG. 3 shows a graph of Bolus 1—MT30—VaselineTM erosion rate as measured by mean alloy erosion rate (mm) by week;
  • FIG. 4 shows a graph of Bolus 2—MT31—Linseed Oil erosion as measured by the mean length of alloy (mm) measured by week;
  • FIG. 5 shows a graph of Bolus 2—MT31—Linseed Oil erosion rate as measured by mean alloy erosion rate (mm) by week;
  • FIG. 6 shows a graph of Bolus 3—MT32—Liquid Paraffin erosion as measured by the mean length of alloy (mm) measured by week;
  • FIG. 7 shows a graph of Bolus 3—MT32—Liquid Paraffin erosion rate as measured by mean alloy erosion rate (mm) by week;
  • FIG. 8 shows a graph of Bolus 4—MT33—Control erosion as measured by the mean length of alloy (mm) measured by week;
  • FIG. 9 shows a graph of Bolus 4—MT33—Control erosion rate as measured by mean alloy erosion rate (mm) by week;
  • FIG. 10 shows a graph comparing the mean weekly alloy erosion (mm) for each bolus used over time. This was calculated by comparing the actual alloy length at the time of reading to the initial length at the start of the trial.
  • the invention is now described with reference to two experiments completed by the inventors to determine the benefits of using a coating in vitro and to determine in vivo the rate of erosion of the bolus of the present invention in the rumen of an animal.
  • a control tablet was produced by weighing on a chemical balance a tablet, then immersing the tablet on edge into the bottom of a 250 ml beaker full of water for 12 hours overnight at room temperature. The tablet was then rinsed gently in warm tap water and the surface padded dry with a paper towel. The tablet was subsequently re-weighed and the 12 hour water absorption determined by subtracting the original weight from the weight post immersion.
  • the coatings tested were silicon spray, vacuum impregnation with resins, vacuum impregnation with light mineral oils (liquid paraffin), application of light mineral oil to the tablet surface by immersion and then drip dry, application of boiled linseed oil by immersion and drip dry and finally application of VaselineTM petroleum jelly onto the surface of the tablets tested.
  • the linseed oil used had a density of 0.942 g/cm 2 at 15.5° C. and a viscosity of approximately 1 Poise at 25° C.
  • the mineral oil used had a density of approximately 0.81 to 0.89 g/cm 2 at 20° C. and a viscosity of 100-140 Poise at 40° C.
  • the VaselineTM used was standard VaselineTM with a viscosity of approximately 640 Poise at 20° C.
  • Vacuum impregnation did not work as the tablets where destroyed in the process.
  • Silicon spray was found to not be very effective at blocking absorption.
  • Example 2 Further in vivo tests were completed in Example 2 using tablets coated in liquid paraffin, linseed oil and VaselineTM to further determine erosion characteristics.
  • the trial involved use of boli in fistulated sheep to evaluate erosion dynamics as a predictor of potential use of the bolus as a successful method for delivery of agents such as anthelmintic compounds.
  • the boli 10 used in the trial ( FIG. 1 ) were made up of a series of cylindrical tablets 11 tightly encased within a magnesium alloy tube 12 which itself was encased in a plastic sheath 13 made up of multiple rings meshed together using a tongue and groove joint to seal the tube. One end of the tube 14 was also sealed by the plastic sheath whilst the opposing end was free of any plastic. The aim was to have erosion occur at the open face end ( 11 , 12 ) and, as the face of each tablet 11 and metal alloy 12 eroded, the plastic rings 13 would drop away.
  • rumen fluids can erode tablets inside the tube rather then purely eroding at the open face. Erosion of tablets and/or alloy deeper in the tube may result in uneven dispersion of active agent, breakdown in the structure of the bolus, lowered duration of time that the bolus remains in the rumen and so on.
  • the tablets used were “blank” starch tablets (same dimensions as envisaged for active containing tablets) interspersed with graphite spacer tablets.
  • the ideal weekly erosion rate of the current alloy was considered to be 0.5 mm/day. Measurements and subsequent analysis were based around this erosion rate although it should be appreciated by those skilled in the art that other rates could be used or designed for without departing from the overall concept of trying to regulate the rate of erosion and avoid uneven erosion rates.
  • the bolus length (mm) from the base to the top of the exposed tablet and the magnesium alloy length (mm) were measured and recorded once weekly using digital vernier callipers.
  • Bolus 2 and 3 (MT31 and MT32) eroded at a faster rate and were completely eroded by the end of the trial duration (20 weeks).
  • the overall alloy erosion dynamics varied between the different boli from week to week and also from comparison with the initial reading. The greatest differences were seen in the comparisons on a weekly basis. The R 2 values for all boli had a range of up to 0.6. There are obvious differences in the erosion dynamics of the alloy depending on what the weekly readings were compared with (either by comparison on a week to week basis or by comparison of the initial reading to the actual reading).
  • the mean erosion rate for VaselineTM compared on a week by week basis was 0.49 mm/day, this compared to 0.43 mm/day for the Control boli.
  • Coatings appear to help in smoothing the rate of erosion of tablets and alloy from the bolus.
  • an erosion rate of 0.5 mm/day the best results were found when the bolus was coated with a more viscous and water immiscible substance such as VaselineTM (Bolus 1—MT30).
  • coating tablets used in the bolus appears to solve the problem in the art of uneven erosion rates which, when active agents are used, could result in uneven dosing of agent(s).
  • a preferred form of coating was found to be VaselineTM but it should be appreciated that other similar viscous and water immiscible substances may be used without departing from the scope of the invention.
  • an aim of the present invention was to achieve an erosion rate of 0.5 mm/day, those skilled in the art should appreciate from the above results, that although faster erosion rates may result, other water immiscible substances may be used such as the oils to smooth the rate of erosion.

Abstract

The present invention relates to a bolus for administration to a ruminant by deposition into its rumen, wherein the bolus has a construction including: a) a casing; b) a core inside the casing wherein the core is formed from at least two tablets; and, is characterised in that a permanently amorphous substance at least partially coats one or more of the tablet or tablets. A method of forming such a bolus is also claimed.

Description

    TECHNICAL FIELD
  • The present invention relates to an improved bolus.
  • More specifically, the invention relates to an improved bolus and method of manufacture using coatings to prevent variation in bolus erosion rates.
  • BACKGROUND ART
  • A wide variety of boli have been used for treatment of livestock such as cows and sheep over many years. The basic premise of the bolus is that an active agent is delivered to the animal over an extended period of time.
  • An advantage of this method of delivery is that the farmer or livestock manager need only administer the bolus once for delivery over an extended period of time rather than having to administer a medication on a more frequent e.g. daily basis. Existing boli may have a useful time period of over one month and therefore this may reduce labour and material costs.
  • However, there are problems with existing boli. By way of example, the bolus described in U.S. Pat. No. 4,649,042 (equivalent to NZ212181) comprises a biodegradable polymeric core impregnated with medicament that is encased in a stainless steel tube with end caps and an arrangement of holes to allow the passage of rumen fluid to the biodegradable core.
  • A layer of settable and/or elastic sealant holds the core in place and prevents seepage of rumen fluid between the walls of the bolus (the tube) and the core which would result in unpredictable delivery of medicament.
  • The required physical properties of the sealant are described as ‘the ability to form a moisture-tight adhesive bond to the polymeric core and to the tube, and a high degree of water impermeability to prevent permeation of water through the layer of sealant to the sides of the core.
  • It is also necessary that the sealant be sufficiently cohesive and elastic to absorb relative movement of the core and tube during thermal expansion and contraction over the temperature range encountered in storage and use, from about −20° C. to about 50° C.
  • However, the degree of elasticity offered by settable sealants can be limited. Cracks or other flaws may develop over time, permitting the ingress of undesired rumen fluid into the core of the bolus.
  • Another problem with settable sealants is that they do not necessarily break down at the same rate as the tablet core. It can be that the settable coatings protects portions of the tablet core better than other portions, leading to inconsistent rates of erosion of the tablet, depending on how the tablet core is physically eroded.
  • A further issue is that the settable sealant can break away in large sections from the bolus, thus becoming a non-contiguous coating along portions of the tablet core. This exposes a much greater portion of the tablet core to the rumen fluid than is ideal, and again, can lead to inconsistent rates of erosion of the tablet.
  • As may be appreciated by those skilled in the art, the spent metal shell of the bolus remains in the rumen after all the biologically active material has been released or paid out. This can cause a problem during slaughter of the animal particularly since the bolus is made of metal which can be hazardous or damage cutting equipment used in slaughter and processing.
  • Another type of bolus described in NZ220024 (equivalent to U.S. Pat. No. 4,863,455) attempts to resolve the problem of residues left in the animal.
  • NZ220024 describes a bolus for administration to a ruminant. It comprises a magnesium-alloy tube filed with a core of a mixture of biologically active material and electronically conductive material lower in the electrochemical series than magnesium. The corrosion is galvanic in nature with a potential difference existing between the tube and core.
  • The tube may be provided with a resin or plastic sheath on its exterior surface to protect the walls of the tube from corrosion by rumen juices. A tube ending is left unprotected to allow gradual corrosion down the length of the tube ideally at the unprotected face. The core may be a single tablet or a series of tablets which are formed in a pelleting die and introduced into the tube or alternatively the ingredients can be forced into the tube using a hydraulic or mechanical press to form a single tablet. The tablet or tablets are said to form a “close fit” with the tube. The use of a series of tablets allows for sequential dosing of different active ingredients or pulse dosing of the same ingredient by having alternate tablets with and without an active ingredient.
  • As may be appreciated, the above type of bolus has the advantage that all or a substantial amount of the bolus dissolves in the rumen with any remaining parts being excreted.
  • One problem with this bolus (and many other boli) is that the bolus described can lose integrity by breakdown of the core elsewhere than at the outward face resulting in premature release of tablets or inconsistent pay out of tablets while in situ in the rumen.
  • In addition, even without significant breakdown described above, the rate of erosion can vary considerably even in “normal” operation.
  • As may be appreciated by those skilled in the art, it may be important that the rate of erosion from a bolus be maintained at an approximately constant rate. If the animal receives a dose greater than that desired, for example by a fast erosion rate or breakdown, release of the active agent may also be at a faster level and therefore may be harmful to the animals.
  • At the very least, a fast erosion rate may give a false sense of security to the farmer in that the animal may have a shorter duration of agent delivery than that expected. A fast release rate may also be toxic to the animal. At the other extreme, if the erosion rate is too slow, the animal may receive insufficient active agent for the application required. For some agents such as anthelmintics, low dosage can result in the development of drug resistance.
  • One issue in arriving at smooth erosion rate is that of egress of rumen fluids into the bolus causing erosion at more than just the interface of the bolus with the fluid. For example, one potential mode of egress is by capillary action with rumen fluid travelling down the inside of the alloy casing and thereby eroding the outside surface of a tablet or tablets contained in the core.
  • The effect of this is that the animal may receive considerably higher doses than that intended or may even receive unplanned pulsed doses rather than a regular smooth dose. In the pulse dose example, capillary action may dissolve a tablet that is not at the designed interface causing both the interface tablet and tablet behind the initial interface to dissolve simultaneously and be released into the animal's bloodstream concurrently, thereby increasing the dose momentarily before a potential ‘no dose’ time period after the tablets erode and a new tablet begins delivery.
  • In the case of anthelmintics, this variation can have significant negative effects. For example, an increased dose could be harmful to the animal. Also the ‘no dose’ time period allows parasites to grow and multiply resulting in loss of livestock condition.
  • It should be appreciated from the above discussion that there are at least two problems with existing boli. The first relates to disposability of the bolus from the animal rumen and the second of controlling erosion rate and avoiding egress of rumen fluids into the bolus too early thereby influencing agent dosing and bolus duration of action.
  • It is an object of the present invention to address the foregoing problems or at least to provide the public with a useful choice.
  • All references, including any patents or patent applications cited in this specification are hereby incorporated by reference. No admission is made that any reference constitutes prior art. The discussion of the references states what their authors assert, and the applicants reserve the right to challenge the accuracy and pertinency of the cited documents. It will be clearly understood that, although a number of prior art publications are referred to herein, this reference does not constitute an admission that any of these documents form part of the common general knowledge in the art, in New Zealand or in any other country.
  • It is acknowledged that the term ‘comprise’ may, under varying jurisdictions, be attributed with either an exclusive or an inclusive meaning. For the purpose of this specification, and unless otherwise noted, the term ‘comprise’ shall have an inclusive meaning—i.e. that it will be taken to mean an inclusion of not only the listed components it directly references, but also other non-specified components or elements. This rationale will also be used when the term ‘comprised’ or ‘comprising’ is used in relation to one or more steps in a method or process.
  • Further aspects and advantages of the present invention will become apparent from the ensuing description which is given by way of example only.
  • DISCLOSURE OF THE INVENTION
  • According to one aspect of the present invention there is provided a bolus for administration to a ruminant by deposition into its rumen, the bolus having a construction including:
      • a) a casing;
      • b) a core inside the casing wherein the core is formed from at least two tablets; and,
        characterised in that a permanently amorphous substance at least partially coats one or more of the tablet or tablets.
  • For the purposes of this specification, the term ‘permanently amorphous’ refers to the coating layer being a non-settable substance that slows the rate of erosion of the core by rumen fluids.
  • The term ‘erosion’ refers to the breakdown into particulate form that occurs when the bolus casing and tablet(s) are exposed to rumen fluids or other aqueous solutions.
  • The invention broadly relates to a bolus for use in ruminants which delivers an active agent or agents to the animal.
  • Preferably, the bolus includes a casing which contains a core of one or more tablets that may include biologically active agents.
  • In preferred embodiments, the casing is made of an alloy of some type, but this should not be seen as limiting. Other casing materials may be used, for example biodegradable plastic or cellulose.
  • In one preferred embodiment, the casing defines a tube shape with an approximately circular cross-section. It should be appreciated that other shapes may also be used such as ellipses or cuboid shapes but a tube is preferable for easy tooling and manufacture since most tabulating machines produce tablets in a circular shape.
  • In a preferred embodiment, the casing may be coated with a water impermeable material such as plastic or rubber on its outer surface to prevent the casing from being corroded on selected surfaces by rumen fluid.
  • In one embodiment, each distal end of the bolus tube may be left uncovered. Rumen fluids then erode the uncovered ends of the bolus eroding back the facing tablet and casing cross-section. In an alternative embodiment, one end of the bolus is also covered in water impermeable plastic so that erosion occurs only at the opposing distal end of the bolus.
  • In one embodiment, the water impermeable coating is a series of plastic rings on the outer surface that are intermeshed together to form a liquid impermeable surface. In one preferred embodiment, the rings are intermeshed using a tongue and groove joint between rings. As the casing and core tablets erode, the rings become loose and eventually fall away from the bolus and are excreted from the rumen.
  • This bolus has the advantage of the bolus structure either eroding away as particles or as small rings which are excreted by the animal with few if any residues. Any metal used such as an alloy casing are dissolved and therefore remove any slaughter and processing issues. As noted in the background section above, a disadvantage of many existing devices, particularly those including metals, is that they remain present in the rumen and, when the animal is sent to slaughter, can damage freezing works machinery.
  • The core includes one or more tablets which is eroded by rumen fluid to release active agents which may be beneficial to the animal being treated.
  • In one preferred embodiment, the active agents may include anthelmintic compounds such as abamectin and ivermectin and the bolus administered to control to parasite infestation. When introduced to the rumen, the bolus slowly erodes due to mixing with rumen fluids, releasing active agent from the tablet or tablets.
  • However, persons skilled in the art will appreciate that a wide variety of agents may used in the present invention, according to the requirements of the user. For example, the active agents may be nutritional supplements such as vitamins or the like.
  • In one preferred embodiment, the core material may contain electronically conductive material lower in the electrochemical series than the alloy used for the bolus casing. As should be appreciated in this embodiment, the corrosion is galvanic in nature with a potential difference existing between the alloy casing and core. The permanently amorphous coating alters the corrosion pattern.
  • Preferably, each tablet included in the core contains at least one active agent mixed with electronically conductive material lower in the electrochemical series.
  • Preferably, the electronically conductive material lower in the electrochemical series is graphite.
  • In this embodiment of the invention, the alloy is magnesium based with magnesium comprising approximately 70 to 98% of the alloy. Such alloys are known in the art and erode in the presence of rumen fluids, particularly where the core includes electronically conductive material lower in the electrochemical series, yet maintain their structural integrity when stored in the absence of aqueous solutions.
  • In the above embodiment, the aim is to control or further manipulate the rate of galvanic corrosion using at least one permanently amorphous substance.
  • In a further embodiment of the present invention, each active containing tablet may be interspaced with a blank or non-active containing tablet. In this embodiment, blank tablets are preferably formed from graphite and active containing tablets in this embodiment may be formed from a starch base. In a further variation to this embodiment, active agent may be carried in the graphite and the remaining tablets may be starch based blanks.
  • It should be appreciated that in the embodiments described above, the way the core is loaded and placement of blanks (if used) will result in active agent(s) being released on a continuous basis or on a pulse basis as may be required depending on the application.
  • In preferred embodiments, the permanently amorphous substance is an oily or oil based substance. However, this should not be seen as limiting. A number of substances have properties which lend themselves to being permanently amorphous. For example, the permanently amorphous substance may be a silicone based grease.
  • Preferably, the permanently amorphous substance has a similar viscosity to Vaseline™ or is a petroleum jelly like Vaseline™, although other permanently amorphous substances with lower viscosities may also be used without departing from the scope of the invention. Examples of such substances include oils such as linseed oil and mineral oils such as liquid paraffin.
  • It is understood by the inventors that the extra viscosity provided by substances such as Vaseline is important where a slower rate of erosion is desired. The higher viscosity of the these substances makes it harder for rumen fluids to erode the tablet(s) and therefore achieve longer delivery time periods.
  • It should be appreciated that where a faster rate of erosion is desired (and a steady rate) other permanently amorphous substances may be preferable. Irrespective of rate though, coatings have been found to reduce erosion rate variation.
  • As may be appreciated form the above description, the permanently amorphous substance may be applied in various ways to the core of the bolus.
  • It should be appreciated that the location of where the tablet(s) have the substance applied will influence the rate and/or smoothness of release. For example, in applications where there is some tolerance for variation in the speed of release, only the tablet face(s) need have the substance coated.
  • In other applications where a tighter erosion control may be desired, the whole of each tablet may be coated. In a yet further embodiment, the tablet(s) may only be coated on the outer ring area and the face(s) remain uncovered. It should therefore be appreciated that by varying the location of the coating, the erosion rate may be controlled.
  • Another advantage of using a permanently amorphous coating such as Vaseline™, is the ability of the coating to remain in place despite any flexing or movement that may occur in the bolus, both in storage and use. For example, it is known that the bolus may contract or expand depending on the temperature. In boluses which have a settable coating, such as that discussed in the prior art, the settable coating can crack or otherwise fail, permitting undesired ingress of rumen fluid to the core.
  • A further advantage is the amorphous nature of the coating of the present invention allows it to better fill in any gaps, cracks or other flaws that may be present or develop in the bolus casing or tablet core. Settable coatings are relatively inflexible once set, so any flaws in the bolus casing or tablet core which may develop after the coating has set may not be adequately protected.
  • According to a further aspect of the present invention there is provided a method of forming a bolus including a casing and a core containing tablets for delivery of an active agent or agents to the rumen of an animal wherein the method includes the steps of:
      • (a) producing a tablet or tablets containing active agent or agents;
      • (b) at least partially coating one or more of the tablets from step (a) with at least one permanently amorphous substance;
      • (c) packing at least two tablets into a casing to form a bolus wherein at least one of the tablets packed into the casing is produced from step (b).
  • Preferably, the tablet or tablets used in the core are formed in a pelleting die sized such that the tablet or tablets form a snug fit within the casing.
  • In one embodiment, the casing is packed with both active agent tablets and blank or non-active agent tablets.
  • Preferably, where blank tablets are used, these are also at least partially coated in a permanently amorphous substance.
  • In one embodiment, the casing is coated with a water impermeable material after step (c) with either one or both ends of the bolus not covered in water impermeable material. In an alternative embodiment, the casing is coated with a water permeable material before step (c) with either one or both ends of the bolus left open and uncovered.
  • It should be appreciated from the above description that there is provided a bolus and method of manufacture that attempts to solve the problem of variation in rates of erosion of a bolus.
  • The method utilises permanently amorphous substances such as oils to in effect slow the egress of rumen fluids and therefore smooth out the rate of erosion compared to that which would be observed if no permanently amorphous substances were used.
  • The use of oils as the permanently amorphous substance reduce the capillary action that may take place in the alloy casing, which contributes to a consistent erosion rate.
  • The use of permanently amorphous substances such as Vaseline™ offers a number of advantages over the prior art:
      • The use of permanently amorphous substances as a coating for the tablet core of a bolus provides a consistent and smooth erosion rate for the tablets.
      • Permanently amorphous substances may also provide superior protection for bolus tablets when the bolus is subject to fluctuations in the shape of the bolus due to temperature changes.
      • Permanently amorphous substances may provide better coverage of the bolus tablet core than settable coatings, filling in any flaws that may develop in the tablet core over time.
      • Permanently amorphous substances are more contiguous with the tablet core, providing superior and consistent protection of the core in the long term.
    BRIEF DESCRIPTION OF THE DRAWINGS
  • Further aspects of the present invention will become apparent from the following description which is given by way of example only and with reference to the accompanying drawings in which:
  • FIG. 1: illustrates a perspective view of a bolus used in trials;
  • FIG. 2: shows a graph of Bolus 1—MT30—Vaseline™ erosion as measured by the mean length of alloy (mm) measured by week;
  • FIG. 3: shows a graph of Bolus 1—MT30—Vaseline™ erosion rate as measured by mean alloy erosion rate (mm) by week;
  • FIG. 4: shows a graph of Bolus 2—MT31—Linseed Oil erosion as measured by the mean length of alloy (mm) measured by week;
  • FIG. 5: shows a graph of Bolus 2—MT31—Linseed Oil erosion rate as measured by mean alloy erosion rate (mm) by week;
  • FIG. 6: shows a graph of Bolus 3—MT32—Liquid Paraffin erosion as measured by the mean length of alloy (mm) measured by week;
  • FIG. 7: shows a graph of Bolus 3—MT32—Liquid Paraffin erosion rate as measured by mean alloy erosion rate (mm) by week;
  • FIG. 8: shows a graph of Bolus 4—MT33—Control erosion as measured by the mean length of alloy (mm) measured by week;
  • FIG. 9: shows a graph of Bolus 4—MT33—Control erosion rate as measured by mean alloy erosion rate (mm) by week;
  • FIG. 10: shows a graph comparing the mean weekly alloy erosion (mm) for each bolus used over time. This was calculated by comparing the actual alloy length at the time of reading to the initial length at the start of the trial.
  • BEST MODES FOR CARRYING OUT THE INVENTION
  • The invention is now described with reference to two experiments completed by the inventors to determine the benefits of using a coating in vitro and to determine in vivo the rate of erosion of the bolus of the present invention in the rumen of an animal.
  • Example 1
  • Premature failure of the bolus and tablets was noted from a bolus similar to that described in NZ220024. Other manufacturing steps such as increasing the amount of compaction (making the tablets harder) were tested and the same problems occurred.
  • In this trial simple immersion tests were completed using various coatings on tablets to determine what if any improvements could be made in slowing the rate of egress of aqueous liquid into tablets.
  • Method
  • A control tablet was produced by weighing on a chemical balance a tablet, then immersing the tablet on edge into the bottom of a 250 ml beaker full of water for 12 hours overnight at room temperature. The tablet was then rinsed gently in warm tap water and the surface padded dry with a paper towel. The tablet was subsequently re-weighed and the 12 hour water absorption determined by subtracting the original weight from the weight post immersion.
  • Various substances were then coated onto further tablets to determine what effect if any these would have on preventing water absorption.
  • The coatings tested were silicon spray, vacuum impregnation with resins, vacuum impregnation with light mineral oils (liquid paraffin), application of light mineral oil to the tablet surface by immersion and then drip dry, application of boiled linseed oil by immersion and drip dry and finally application of Vaseline™ petroleum jelly onto the surface of the tablets tested.
  • The linseed oil used had a density of 0.942 g/cm2 at 15.5° C. and a viscosity of approximately 1 Poise at 25° C.
  • The mineral oil used had a density of approximately 0.81 to 0.89 g/cm2 at 20° C. and a viscosity of 100-140 Poise at 40° C.
  • The Vaseline™ used was standard Vaseline™ with a viscosity of approximately 640 Poise at 20° C.
  • Results
  • Vacuum impregnation did not work as the tablets where destroyed in the process.
  • Silicon spray was found to not be very effective at blocking absorption.
  • Immersion in mineral oil, boiled linseed oil and Vaseline™ petroleum jelly gave results that were about ½ to ⅔rds less absorption when compared with control (no coating) tablet.
  • Further in vivo tests were completed in Example 2 using tablets coated in liquid paraffin, linseed oil and Vaseline™ to further determine erosion characteristics.
  • Example 2 In Vivo Trial Background
  • The trial involved use of boli in fistulated sheep to evaluate erosion dynamics as a predictor of potential use of the bolus as a successful method for delivery of agents such as anthelmintic compounds.
  • The boli 10 used in the trial (FIG. 1) were made up of a series of cylindrical tablets 11 tightly encased within a magnesium alloy tube 12 which itself was encased in a plastic sheath 13 made up of multiple rings meshed together using a tongue and groove joint to seal the tube. One end of the tube 14 was also sealed by the plastic sheath whilst the opposing end was free of any plastic. The aim was to have erosion occur at the open face end (11,12) and, as the face of each tablet 11 and metal alloy 12 eroded, the plastic rings 13 would drop away.
  • As noted in the background of this specification, a problem with such boli is that rumen fluids can erode tablets inside the tube rather then purely eroding at the open face. Erosion of tablets and/or alloy deeper in the tube may result in uneven dispersion of active agent, breakdown in the structure of the bolus, lowered duration of time that the bolus remains in the rumen and so on.
  • In the trial completed, four types of bolus were used. Three of the boli contained a series of tablets with the face of each tablet being coated as a smear prior to assembly into a tube. The fourth bolus type used was negative control that did not have any coating applied to the tablets inside the tube. Coatings were applied to investigate whether or not the additional coating had an effect on erosion dynamics and leakage.
  • In summary, the boli used were as follows:
      • 1. Bolus 1—MT30—Vaseline™ coated
      • 2. Bolus 2—MT31—Linseed Oil coated
      • 3. Bolus 3—MT32—Liquid Paraffin coated
      • 4. Bolus 4—MT33—Plain (Control); no additional treatment coating.
  • For the purposes of the trial, the tablets used were “blank” starch tablets (same dimensions as envisaged for active containing tablets) interspersed with graphite spacer tablets.
  • The overall dimensions and weight were the same for all boli variations, with all resulting boli having a weight of roughly 182 g, a volume of 67.7 cc and a density of 2.69 g/cc.
  • For a preferred embodiment of the invention, the ideal weekly erosion rate of the current alloy was considered to be 0.5 mm/day. Measurements and subsequent analysis were based around this erosion rate although it should be appreciated by those skilled in the art that other rates could be used or designed for without departing from the overall concept of trying to regulate the rate of erosion and avoid uneven erosion rates.
  • Method
  • Boli from each treatment group were administered (one per animal) to rumen-fistulated sheep n=9 for all four variations of the boli, thus n=36 in total. The sheep were maintained on standard ryegrass/clover pasture with some additional hay (due to poorer winter grazing) for the duration of the trial. They were brought into a shed on a weekly basis to allow for measurements to be taken.
  • The bolus length (mm) from the base to the top of the exposed tablet and the magnesium alloy length (mm) were measured and recorded once weekly using digital vernier callipers.
  • The trial ran for a total of 20 weeks although measurements for Bolus 2—MT31—Linseed Oil and Bolus 3—MT32—Liquid Paraffin ceased part way.
  • Results
  • The results are now discussed with reference to FIGS. 2 to 10.
  • Mean Length of Alloy
  • As shown in FIGS. 2, 4, 6 and 8, initially, all the alloys within the boli were around 98 mm in length. By week 20, the mean readings were 28.8 mm and 33.8 mm respectively for the Vaseline™ coated and Control boli (MT30 and MT33). The R2 value for all four boli was always within a range of 0.05.
  • Bolus 2 and 3 (MT31 and MT32) eroded at a faster rate and were completely eroded by the end of the trial duration (20 weeks).
  • Alloy Erosion Rate
  • As shown in FIGS. 3, 5, 7, 9 and 10, the overall alloy erosion dynamics varied between the different boli from week to week and also from comparison with the initial reading. The greatest differences were seen in the comparisons on a weekly basis. The R2 values for all boli had a range of up to 0.6. There are obvious differences in the erosion dynamics of the alloy depending on what the weekly readings were compared with (either by comparison on a week to week basis or by comparison of the initial reading to the actual reading).
  • The results indicate that the Vaseline™ coated boli were closest to having the desired erosion rate of 0.5 mm/day for both the week to week comparison and the actual to the initial comparison (mean=0.49 mm and 0.52 mm respectively).
  • In general all boli, to differing extents, appeared to follow a trend that prior to and when a tablet paid out the erosion rate increased.
  • The mean erosion rate for Vaseline™ compared on a week by week basis was 0.49 mm/day, this compared to 0.43 mm/day for the Control boli.
  • It was noted that during the time period that the Liquid Paraffin and Linseed Oil were eroding, they exhibited faster erosion rates compared to the other two with mean erosion rates (compared on a week by week basis) of 0.54 mm/day and 0.57 mm/day respectively but with a smoother rate of release than the Control bolus.
  • Conclusions
  • Coatings appear to help in smoothing the rate of erosion of tablets and alloy from the bolus. For the preferred embodiment of an erosion rate of 0.5 mm/day, the best results were found when the bolus was coated with a more viscous and water immiscible substance such as Vaseline™ (Bolus 1—MT30).
  • Despite other coatings eroding faster than 0.5 mm/day, these coatings also gave more consistent erosion rates than the control which did not utilize a coating.
  • Results indicate that the different coatings had an effect on erosion dynamics of the boli and that the previous problem of leakage to the underlying tablets appears to have improved greatly with the use of water immiscible coatings.
  • As should be appreciated from the above trial example, coating tablets used in the bolus appears to solve the problem in the art of uneven erosion rates which, when active agents are used, could result in uneven dosing of agent(s).
  • A preferred form of coating was found to be Vaseline™ but it should be appreciated that other similar viscous and water immiscible substances may be used without departing from the scope of the invention. In addition, whilst an aim of the present invention was to achieve an erosion rate of 0.5 mm/day, those skilled in the art should appreciate from the above results, that although faster erosion rates may result, other water immiscible substances may be used such as the oils to smooth the rate of erosion.
  • Aspects of the present invention have been described by way of example only and it should be appreciated that modifications and additions may be made thereto without departing from the scope thereof as defined in the appended claims.

Claims (17)

1. A bolus for administration to a ruminant by deposition into its rumen, the bolus having a construction including:
a casing;
b) a core inside the casing wherein the core is formed from at least two tablets; and,
characterised in that a permanently amorphous substance at least partially coats one or more of the tablet or tablets.
2. A bolus as claimed in claim 1 wherein the permanently amorphous substance is an oil based substance.
3. A bolus as claimed in claim 1 wherein the permanently amorphous substance is petroleum jelly.
4. A bolus as claimed in claim 1 wherein the permanently amorphous substance is liquid paraffin.
5. A bolus as claimed in claim 1 wherein the casing is coated with a water impermeable material.
6. A bolus as claimed in claim 5 wherein the water impermeable material is plastics material.
7. A bolus as claimed in claim 6 wherein the plastics material is in the form of a series of intermeshed plastic rings.
8. A bolus as claimed in claim 7 wherein the rings are intermeshed using a tongue and groove joint between rings.
9. A bolus as claimed in claim 1 wherein the casing is a tubular shape with an approximately circular cross-section.
10. A bolus as claimed in claim 1 wherein the casing is an alloy casing.
11. A bolus as claimed in claim 10 wherein the tablets of the core contain electrically conductive material lower in the electrochemical series than the constituents of the alloy casing.
12. A bolus as claimed in claim 11 wherein the electrically conductive material of the core is graphite.
13. A bolus as claimed in claim 10 wherein the alloy casing is magnesium based.
14. A bolus as claimed in claim 13 wherein the magnesium forms approximately 70 to 98% of the alloy casing.
15. A method of forming a bolus including a casing and a core containing tablets for delivery of an active agent or agents to the rumen of an animal wherein the method includes the steps of:
(a) producing a tablet or tablets containing active agent or agents;
(b) at least partially coating one or more of the tablets from step (a) with at least permanently amorphous substance;
(c) packing at least two tablets into a casing to form a bolus wherein at least one of the tablets packed into the casing is produced from step (b).
16. A method of forming a bolus as claimed in claim 15 wherein the method includes an additional step of:
(d) coating the casing with an water impermeable material with either one or both ends of the bolus not covered in water impermeable material.
17-18. (canceled)
US13/131,260 2008-11-25 2009-08-21 Bolus Abandoned US20110287081A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ573143 2008-11-25
NZ573143A NZ573143A (en) 2008-11-25 2008-11-25 Improvements in delivery devices
PCT/NZ2009/000173 WO2010062191A1 (en) 2008-11-25 2009-08-21 Improved bolus

Publications (1)

Publication Number Publication Date
US20110287081A1 true US20110287081A1 (en) 2011-11-24

Family

ID=42040796

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/131,259 Active US8329206B2 (en) 2008-11-25 2009-06-29 Bolus devices for the delivery of active agents to animals
US13/131,260 Abandoned US20110287081A1 (en) 2008-11-25 2009-08-21 Bolus

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US13/131,259 Active US8329206B2 (en) 2008-11-25 2009-06-29 Bolus devices for the delivery of active agents to animals

Country Status (8)

Country Link
US (2) US8329206B2 (en)
EP (2) EP2361053B1 (en)
AU (2) AU2009320500B2 (en)
BR (1) BRPI0921187A2 (en)
ES (1) ES2911226T3 (en)
NZ (1) NZ573143A (en)
WO (2) WO2010062190A1 (en)
ZA (2) ZA201104724B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103126886A (en) * 2011-05-13 2013-06-05 中国农业科学院北京畜牧兽医研究所 Piglet soothing agent releasing box
WO2022124914A1 (en) 2020-12-08 2022-06-16 Ruminant Biotech Corp Limited Improvements to devices and methods for delivery of substances to animals

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219572A (en) * 1989-03-17 1993-06-15 Pitman-Moore, Inc. Controlled release delivery device for macromolecular proteins
US5558878A (en) * 1991-06-27 1996-09-24 Captab, L.L.C. Method for blinding a tableted medication

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1133278A (en) * 1978-02-03 1982-10-12 Imperial Chemical Industries Limited Gas analysis
US4418686A (en) * 1979-08-01 1983-12-06 Child Laboratories Inc. Implant for inhibiting mastitis in dairy cattle
US4381780A (en) * 1981-01-19 1983-05-03 Research Corporation Sustained release delivery system
GR851195B (en) * 1984-06-02 1985-11-25 Castex Prod
GB8514666D0 (en) 1985-06-11 1985-07-10 Coopers Animal Health Agent delivery systems
AU605482B2 (en) * 1986-04-17 1991-01-17 Castex Products Limited Pellet for administration to ruminants
GB9023270D0 (en) * 1990-10-25 1990-12-05 Castex Prod Magnesium manganese alloy
CA2181693C (en) * 1994-01-20 2006-09-19 Rex Munday Device for administration of beneficial materials to ruminants
GB9801141D0 (en) * 1998-01-21 1998-03-18 Porter William L Bolus for ruminent animals
US6030367A (en) * 1999-03-22 2000-02-29 Bracco Research Plunger rod
GB0111391D0 (en) * 2001-05-10 2001-07-04 Porter William L Pulse release bolus
NZ519363A (en) 2002-06-05 2004-02-27 Agres Ltd A novel drug dosing regimen
CN1964748A (en) * 2004-04-06 2007-05-16 苏莫迪克斯公司 Coating compositions for bioactive agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219572A (en) * 1989-03-17 1993-06-15 Pitman-Moore, Inc. Controlled release delivery device for macromolecular proteins
US5558878A (en) * 1991-06-27 1996-09-24 Captab, L.L.C. Method for blinding a tableted medication

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Bibliographic Information Page for PCT/NZ2009/000173 (WIPO [Downloaded June 3, 2013]), 1 page. *
Certification Page for PCT/NZ2009/000173 (WIPO, 2009), 1 page. *
Ullman's Encyclopedia of Industrial Chemistry ("Ullman") (Vol. 39 (Wiley-VCH Verlag Gmbh & co. KGaA, Weineheim, 2012) (Published on-line 15 June 2000), Waxes, pp. 112 - 172, excerpt provided, pp. 113, 119, 127, 135, 136, 138, 144, 146 - 148, 150 - 152), 14 pages. *

Also Published As

Publication number Publication date
EP2361053B1 (en) 2022-01-19
AU2009320501B2 (en) 2014-08-21
ZA201104724B (en) 2012-12-27
AU2009320500A1 (en) 2011-07-07
EP2361053A1 (en) 2011-08-31
EP2361055A4 (en) 2013-12-18
US20110280923A1 (en) 2011-11-17
AU2009320501A1 (en) 2011-07-07
EP2361055A1 (en) 2011-08-31
ZA201104723B (en) 2012-12-27
US8329206B2 (en) 2012-12-11
NZ573143A (en) 2010-03-26
WO2010062191A1 (en) 2010-06-03
EP2361053A4 (en) 2013-12-25
ES2911226T3 (en) 2022-05-18
AU2009320500B2 (en) 2014-09-25
BRPI0921187A2 (en) 2016-02-23
WO2010062190A1 (en) 2010-06-03

Similar Documents

Publication Publication Date Title
US4578263A (en) Pharmaceutical pellet
EP0164927B1 (en) Release devices
EP2459116B1 (en) Sustained release capsules
JPS62283918A (en) Pulse type drug releasing system
AU697144B2 (en) Device for administration of beneficial materials to ruminants
US5342576A (en) Magnesium manganese alloy
ATE285228T1 (en) DRUG ADMINISTRATION SYSTEM FOR DELAYED, COMPLETE RELEASE OF ACTIVE INGREDIENTS IN THE DIGESTIVE TRACT
AU2009320501B2 (en) Improved bolus
US5074857A (en) Bolus for releasing a biologically active substance into a liquid environment
NZ573142A (en) Improved bolus
AU2023200196A1 (en) Improvements to devices and methods for delivery of substances to animals
EP0333311B1 (en) Intraruminal drug delivery device
NZ278977A (en) Sustained release bolus for ruminants
AU618318B2 (en) Intraruminal drug delivery device
AU2021221810B2 (en) Improvements to devices and methods for delivery of substances to animals
AU2016200312A1 (en) Sustained release capsules
NZ594862A (en) Sustained release capsule with piston having hollow sleeve on back of piston for guiding spring
NZ578771A (en) Sustained release capsules with overcap rupturable first to allow dose dump before further dose delivered by spring biased piston
ALOORKAR et al. Indian Journal of Novel Drug Delivery
GB2551363A (en) Multi-component bolus
McLellan Development of an Intraruminal Controlled-Release Device
AU2014203209A1 (en) Sustained release capsules

Legal Events

Date Code Title Description
AS Assignment

Owner name: BOMAC RESEARCH LIMITED, NEW ZEALAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LEECH, WAYNE FREDERICK;POMROY, WILLIAM ERNEST;REEL/FRAME:026767/0606

Effective date: 20110731

AS Assignment

Owner name: BAYER NEW ZEALAND LIMITED, NEW ZEALAND

Free format text: MERGER;ASSIGNOR:BOMAC RESEARCH LIMITED;REEL/FRAME:030062/0896

Effective date: 20111231

STCB Information on status: application discontinuation

Free format text: ABANDONMENT FOR FAILURE TO CORRECT DRAWINGS/OATH/NONPUB REQUEST